tiprankstipranks
Trending News
More News >
Tryptamine Therapeutics Limited (AU:ENP)
ASX:ENP
Australian Market
ENP
Tryptamine Therapeutics
RESEARCH TOOLSreports
Advertisement

Tryptamine Therapeutics (ENP) Price & Analysis

Compare
14 Followers

ENP Stock Chart & Stats

Currently, no data available
Please return soon. This page is being updated.

ENP FAQ

What was Tryptamine Therapeutics Limited’s price range in the past 12 months?
Tryptamine Therapeutics Limited lowest share price was AU$0.03 and its highest was AU$0.05 in the past 12 months.
    What is Tryptamine Therapeutics Limited’s market cap?
    Tryptamine Therapeutics Limited’s market cap is AU$54.72M.
      When is Tryptamine Therapeutics Limited’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Tryptamine Therapeutics Limited’s earnings last quarter?
      Currently, no data Available
      Is Tryptamine Therapeutics Limited overvalued?
      According to Wall Street analysts Tryptamine Therapeutics Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Tryptamine Therapeutics Limited pay dividends?
        Tryptamine Therapeutics Limited does not currently pay dividends.
        What is Tryptamine Therapeutics Limited’s EPS estimate?
        Tryptamine Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Tryptamine Therapeutics Limited have?
        Tryptamine Therapeutics Limited has 1,609,510,100 shares outstanding.
          What happened to Tryptamine Therapeutics Limited’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Tryptamine Therapeutics Limited?
          Currently, no hedge funds are holding shares in AU:ENP

          Company Description

          Tryptamine Therapeutics Limited

          Exopharm Ltd is a biopharmaceutical company operating in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. Its products Plexaris and Exomere are developed using LEAP manufacturing process.
          Popular Stocks
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis